WuXi STA, Colorcon Expand Mfg Capabilities, Colorcon Launches Platform

By Emily Forster -

January 9, 2020

The latest news from CDMOs, CMOs, and suppliers featuring news from WuXi STA, Joinn Biologics, and Colorcon.

Chemicals/Chemical API Manufacturing

WuXi STA Opens Oligonucleotide Mfg Facility in China

WuXi STA, a subsidiary of WuXi AppTec, has opened a large-scale oligonucleotide active pharmaceutical ingredient (API) manufacturing facility in Changzhou, China. This facility offers a comprehensive one-stop platform to support the process R&D and manufacture of oligonucleotide APIs from preclinical to commercial.

The new facility, with over 30,000 square feet, is located at WuXi STA’s Changzhou, China site. With its operation, the Changzhou site can manufacture oligonucleotide APIs up to an 1 mol/synthesis run. The Changzhou site can now provide services involving small-molecule, oligonucleotide and peptide process R&D and manufacturing from laboratory to commercial scales. It has successfully passed multiple inspections from the FDA and the National Medical Products Administration.

Source: WuXi STA

Biologics Manufacturing

Joinn Biologics Raises $60 M in Financing for CDMO Biopharma Business

Joinn Biologics, a Richmond, California-based CDMO for biomanufacturing and fill–finish services, has completed a $60-million Series A financing to fund expansion of biomanufacturing as well as business operations in China and the US. The financing was led by Huagai Capital Medical Fund, with Nestbio Capital, Hong Kong Linkage Holdings, Xiangtang Capital and other institutions jointly participating in the investment.

This round of financing will be mainly used to added 100,000s liters of capacity as well as for business expansion in China and the US.

Source: Joinn Biologics

Formulation Development/Drug Product Manufacturing

Colorcon Launches Authentication Platform, Expands Mfg and Supply-Chain Capabilities

Colorcon, a developer of film-coating systems and excipients, and Applied DNA Sciences (ADNAS), a provider of molecular technologies for supply-chain security, have formed a collaboration for on-dose authentication capability for track-and-trace functionality for supply-chain security. Colorcon has also completed an expansion of its North American production facility in West Point, Pennsylvania.

Under its collaboration with ADNAS, the companies focused on the integration of molecular taggants from ADNAS into an Opadry fully formulated coating system. Opadry is a one-step semipermeable membrane designed to ensure consistent release from osmotic pump tablets. This first commercial offering of the collaboration uses intelligent data and analytics gathered from authentication of the dosage form itself.

Separately, Colorcon has completed an expansion and renovation at its US production facility in West Point, Pennsylvania. The multimillion-dollar investment expands supply-chain capabilities for makers of solid oral dosage products throughout the US, Canada, Puerto Rico, Mexico, Colombia, Peru, Bolivia as well as the northern areas of Central and Latin America. The investment has consolidated multiple legacy buildings into one manufacturing campus and has eliminated the need for off-site warehousing.

Source: Colorcon (Launch), Colorcon (Expansion)